Ajanta Pharma Q1 FY26 + FY25 Recap: From “First-to-Market” Drugs to First-Class Tax Raids

1. At a Glance

Ajanta Pharma is that mid-cap pharma kid who always tries to act like a topper: ROE 25%, ROCE 32%, debt-free flex, and 500+ products — half of them “first-to-market.” But the teacher (read: market) still cuts marks, and the stock is down ~19% in one year. Recent highlights? A buyback in 2024, FDA approvals sprinkled like masala on bhel, and an Income Tax raid in August 2025 (because SEBI drama was too mainstream).

2. Introduction

In a pharma industry filled with giants like Sun, Cipla, and Dr. Reddy’s, Ajanta is like that sharp cousin at family functions who brags, “I launched this drug first.” And, to be fair, they usually did.

The strategy is classic: focus on branded generics in India (ophthalmology, cardiology, dermatology, pain management), branded exports in Asia/Africa, and a modest US generics play. What keeps them interesting is their obsession with niche, specialty, hard-to-make drugs rather than playing the same paracetamol game as everyone else.

But being niche doesn’t mean being immune. US price erosion? They felt it. Freight and raw material spikes? They limped. And when everything looked stable, August 2025 saw the taxman arrive at their offices with a “We’re here for chai” notice.

Question for you: Do you prefer companies that chase blockbuster molecules like Bollywood stars chase item numbers, or those that quietly dominate small but sticky niches?

3. Business Model – WTF Do They Even Do?

Ajanta’s three revenue cylinders:

1. India Branded Generics (31%)
   • ~2,800 MRs (sales force) roaming clinics like Swiggy agents.
   • IPM rank: 27 overall, but Top 2 in ophthalmology and pain.
   • 23 launches in FY22, 6 were “first to market.” Basically, they’re that nerdy kid who submits projects before anyone else even buys chart paper.
2. US Generics (22%)
   • From zero revenue in 2016 → ₹828 Cr in FY23.
   • 40 products launched, focusing on delayed/extended release formulations.
   • Two facilities (Dahej, Paithan).
   • But recently slowed capex — US market became the Bigg Boss house: too much drama, no guaranteed winners.
3. Rest of World Branded Generics (41%)
   • Philippines, Middle East, Africa are Ajanta’s NRI cousins sending remittances.
   • 38 launches in FY23, team size up 50%.
   • Unlike US, here they get pricing power because doctors prescribe brands, not chemists pushing the cheapest box.
4. African Institutional (5%)
   • Anti-malarials via WHO pre-qualified products.
   • Lumpy revenues depending on donor agencies. Ajanta realized they can’t rely on Bill Gates’ mood swings, so they shifted focus to branded Africa biz.

Bottom line: Ajanta avoids the high-volume, low-margin paracetamol wars and instead sells “doctor’s pet” specialty pills at premium pricing.

4. Financials Overview

Commentary:

• Margins steady around 27%.
• EPS annualized ≈ ₹81.6 → P/E ~31 at CMP ₹2,539.
• Profits grew, but much slower than sales